A bit more!
$Aldeyra Therapeutics (ALDX.US)$ Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial For Reproxalap Ophthalmic Solution In Treating Dry Eye Disease; Statistically Superior For Ocular Discomfort; NDA Resubmission Anticipated In 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more